In this study, we investigated the association between the drug-induced pulmonary infiltration with eosinophilia (PIE) syndrome in a patient with hypertension and the angiotensin-converting enzyme inhibitor (ACE-I) captopril. Although the patient developed diffuse lung field infiltrates accompanied by productive cough and striking peripheral eosinophilia, these symptomsdisappeared after termination of the administration of captopril, pronase and cephalexine. Furthermore, the results of the peripheral lymphocyte stimulation test, skin patch test and provocation test under informed consent showed a positive reaction only for captopril. Therefore, this patient was diagnosed as captopril-induced PIE syndrome.
Introduction
The angiotensin-converting enzyme inhibitor (ACE-I) captopril is useful for treatment ofhypertension and congestive heart failure. Recently, ACE-I has been reported to be associated with the following side effects: cough as a major side effect ( 1 , 2) , bronchial abnormal response (3), and asthmatic tendency in patients with pre-existing bronchial hyperactivity (4). But the association between the pulmonary infiltration with eosinophilia (PIE) syndrome and ACE-I captopril (5) has seldom been reported.
Case Report
A 58-year-old female accountant, was examined for a common cold and hypertension on May 25, 1988 . She was nonatopic and had no family history of asthma. The blood pressure was 180/90 mmHg and the heart rate was 66/min without arrhythmia. For treatment, she received 37.5 mg of captopril, 27,000 tyrosine unit of pronase and 1,500 mg of cephalexine three times a day for three days. She suffered from severe dry cough with a small amount of sputum, fever and dyspnea two days after the start of administration. Then, she was admitted to our hospital and administration of these drugs was stopped on May 27, 1988. Figure 1 and Table 1 show the clinical course and laboratory data, respectively. Peripheral blood data indicates 13% of eosinophilia with leukocytosis. The chest radiograph (Fig. 2 ) on admission showeddiffuse reticulonodular shadows in the bilateral lung field. The recovery of bronchoalveolar lavage (BALF) was 57% (86 ml/150 ml) and the total cell count was 1.88xlO5 cells/ml with 27.1% eosinophils. A transbronchial lung biopsy on the 1 lth hospital day disclosed alveolar septal fibrosis and predominant eosinophilic infiltration, including eosinophilic pneumonia (Fig. 3) . Figure 1 shows that cough, dyspnea and fever gradually diminished three days after the captopril treatment was stopped. Figure 4 shows that her chest radiograph returned to normal in a week. Consequently the peripheral eosinophilia became nor- dependent manner. Andthe wheal and flare skin response to captopril were observed for 48 hours afterwards. Provocation tests with captopril, pronase and cephalexine under informed consent was performed, and she developed severe cough, dyspnea and nausea two hours after administration of captopril. But the symptoms disappeared after administration of methylprednisolone. On the other hand, no symptomwas observed when she received pronase or cephalexine. These results indicated that she had captopril-induced PIE syndrome.
Discussion
The mechanism of ACE-I-induced cough has been poorly defined. Recently, ACE-I has been reported to activate tachykinins such as bradykinin, substance-P, and enkephaline (7). Activation oftachykinins may cause ACE-I-induced cough. On the other hand, it is thought that the mechanismof druginduced pneumonia is mainly associated with a toxic or allergic reaction (8). In the present study, LST and the skin patch test indicated that the morbidity of ACE-I-induced PIE syndrome was caused not by activation with tachykinins but by an allergic reaction.
Drug-induced pulmonary diseases have been reported as the result of side effect after the administration of various drugs (9).
But there have t>een few reports on drug-induced pulmonary diseases with anti-hypertensive drugs except for diuretics ( 10). Schatz et al (5) reported two patients with hypertension, congestive heart failure and chronic renal failure. They developed peripheral eosinophilia and new lung field infiltrates after rechallenging with captopril. Their immunofluorescent study through transbronchial biopsy indicated an immune-complexmediated lesion. This was the first report of PIE syndrome caused by an allergic reaction to captopril. However, specific allergic tests such as LSTand the skin patch test of captopril were not performed on their patients. On the other hand, we did not perform an immunofluorescent study. The allergic reaction appeared 3 days after administration, which was too short to determine the cause as captopril. But LST, the skin patch and the provocation tests showed the association between PIE syndrome and an allergic reaction to captopril. Then, we diagnosed this patient as captopril-induced PIE syndrome. The problem remaining, was that LST showed positivity for not only captopril but also pronase, but the skin patch test was positive only for captopril. And there were no changes in the subjective symptomsand laboratory data during the provocation test with pronase. It was considered that the positive reaction with pronase in LSTmay have been a false-positive result.
Furthermore, we followed a 55-year-old male with hypertension who developed bilateral lung infiltrates and peripheral eosinophilia caused by the administration ofcaptopril-R. Based on this study, we consider it essential that patients suffering from cough, dyspnea and fever are carefully observed due to the possible development of drug-induced PIE syndrome caused by administration of ACE-I captopril.
